Payment overview · 2025
General Payments
$364.15
25 reported records · 9 companies
Healthcare provider profile · identity verified
Allison Blacksher, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · SAINT JAMES, MO · NPI 1679072169
Verified facts
What the public records show
CMS Open Payments records show Allison Blacksher, PA received $364.15 in general payments during 2025 across 25 reported records.
Amgen Inc. accounted for 37.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $135.50 | 37.2% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $91.41 | 25.1% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.32 | 9.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.96 | 6.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.42 | 5.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.95 | 4.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.93 | 4.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.04 | 4.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.62 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $364.15 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $135.50 | 13 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $130.54 | 12 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $62.38 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.03 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 347 | 68 |
| Atorvastatin Calcium | Atorvastatin Calcium | 301 | 84 |
| Omeprazole | Omeprazole | 300 | 62 |
| Gabapentin | Gabapentin | 270 | 50 |
| Lisinopril | Lisinopril | 262 | 65 |
| Famotidine | Famotidine | 220 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 213 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 209 | 45 |
| Metformin Hcl | Metformin Hcl | 187 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 170 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 170 | 35 |
| Losartan Potassium | Losartan Potassium | 155 | 37 |
| Sertraline Hcl | Sertraline Hcl | 153 | 36 |
| Potassium Chloride | Potassium Chloride | 151 | 42 |
| Furosemide | Furosemide | 138 | 41 |
| Simvastatin | Simvastatin | 135 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 27 |
| Montelukast Sodium | Montelukast Sodium | 103 | 23 |
| Trazodone Hcl | Trazodone Hcl | 101 | 24 |
| Eliquis | Apixaban | 95 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 89 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 89 | 34 |
| Meloxicam | Meloxicam | 88 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 17 |
| Bupropion Xl | Bupropion Hcl | 85 | 20 |
| Lovastatin | Lovastatin | 84 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 81 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 25 |
| Carvedilol | Carvedilol | 75 | 20 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 73 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 72 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 14 |
| Glipizide | Glipizide | 71 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 70 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 70 | 16 |
| Jardiance | Empagliflozin | 67 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 67 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 14 |
| Methylprednisolone | Methylprednisolone | 56 | 47 |
| Mounjaro | Tirzepatide | 56 | suppressed |
| Atenolol | Atenolol | 54 | 13 |
| Chlorthalidone | Chlorthalidone | 54 | 11 |
| Alendronate Sodium | Alendronate Sodium | 52 | 13 |
| Buspirone Hcl | Buspirone Hcl | 52 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Ezetimibe | Ezetimibe | 49 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Finasteride | Finasteride | 45 | 11 |
| Ozempic | Semaglutide | 45 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 44 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 43 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Spironolactone | Spironolactone | 42 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 13 |
| Prednisone | Prednisone | 40 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 26 |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Vascepa | Icosapent Ethyl | 34 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Fluconazole | Fluconazole | 31 | 16 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 16 |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 21 |
| Azithromycin | Azithromycin | 22 | 18 |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Nystatin | Nystatin | 21 | 11 |
| Trulicity | Dulaglutide | 21 | suppressed |
| Azathioprine | Azathioprine | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Jantoven | Warfarin Sodium | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Allopurinol | Allopurinol | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $364.15 · 25 records | Amgen Inc. | Auvelity, CAPLYTA, Cologuard Collection Kit, OTEZLA, REPATHA, REXULTI, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, YUPELRI, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error